| Symbol | GOVX |
|---|---|
| Name | GEOVAX LABS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1900 LAKE PARK DRIVE,SUITE 380, SMYRNA, Georgia, 30080, United States |
| Telephone | +1 678 384-7220 |
| Fax | — |
| — | |
| Website | https://www.geovax.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000832489 |
| Description | Geovax Labs Inc is us-based clinical-stage biotechnology company. Additional info from NASDAQ: |
Director SPENCER JOHN N JR 🟢 acquired 6.0K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021323
Read moreDirector Morgan Jayne 🟢 acquired 6.0K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021322
Read moreDirector MCNALLY ROBERT T 🟢 acquired 6.0K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021321
Read moreDirector Lemerond Nicole 🟢 acquired 6.0K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021320
Read moreDirector Kollintzas Dean G 🟢 acquired 6.0K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021319
Read moreDirector CHASE RANDAL D 🟢 acquired 6.0K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021317
Read moreSharkey John W. 🟢 acquired 17.6K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021316
Read moreReynolds Mark 🟢 acquired 17.6K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021315
Read moreNEWMAN MARK J 🟢 acquired 17.6K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021314
Read moreMcKee Kelly T. Jr. 🟢 acquired 17.6K shares (1 derivative) of GeoVax Labs, Inc. (GOVX) at $1.18 Transaction Date: Jun 17, 2026 | Filing ID: 021312
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04041674 | Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GE… | Phase1 | HIV Infections | Withdrawn | 2022-03-01 | 2023-05-31 | ClinicalTrials.gov |
| NCT04977024 | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With… | Phase2 | COVID-19 Infection | Active_Not_Recruiting | 2021-09-27 | 2027-12-31 | ClinicalTrials.gov |
| NCT04639466 | A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COV… | Phase1 | COVID-19 Infection | Completed | 2020-11-19 | 2025-12-03 | ClinicalTrials.gov |
| NCT04357821 | Combinatorial Therapy to Induce an HIV Remission | Phase1 | HIV/AIDS | Active_Not_Recruiting | 2020-08-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT03754933 | Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphat… | Phase1 | Recurrent Head and Neck Cancer | Completed | 2019-02-11 | 2024-12-31 | ClinicalTrials.gov |
| NCT01571960 | Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen … | Phase1 | HIV Infections | Completed | 2012-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01378156 | A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine … | Phase1 | HIV-1 Infection | Completed | 2010-06-01 | 2014-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Protein Placebo | Other | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |
| IHV01 Protein | Other | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |
| B63521^11 gp120 | Other | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |
| MVA/HIV62B Vaccine | Other | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |
| GEO-D02 DNA | Other | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |
| JS7 plasmid DNA and MVA62B vaccine | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT01378156 |
| Placebo for MVA62B: | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT01571960 |
| Placebo for GEO-D03 DNA | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT01571960 |
| MVA/HIV62B (MVA62B) vaccine | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT01571960 |
| GEO-D03 DNA vaccine | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT01571960 |
| Fludarabine Phosphate | Other | Phase PHASE1 | Recurrent Head and Neck Cancer | COMPLETED | NCT03754933 |
| Ad/PNP | Other | Phase PHASE1 | Recurrent Head and Neck Cancer | COMPLETED | NCT03754933 |
| Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 | Other | Phase PHASE1 | COVID-19 Infection | COMPLETED | NCT04639466 |
| Placebo Administration | Other | Phase PHASE1 | COVID-19 Infection | COMPLETED | NCT04639466 |
| Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 | Other | Phase PHASE2 | COVID-19 Infection | ACTIVE_NOT_RECRUITING | NCT04977024 |
| Diagnostic Laboratory Biomarker Analysis | Other | Phase PHASE2 | COVID-19 Infection | ACTIVE_NOT_RECRUITING | NCT04977024 |
| COVID-19 Vaccine | Other | Phase PHASE2 | COVID-19 Infection | ACTIVE_NOT_RECRUITING | NCT04977024 |
| Combination Intervention | Other | Phase PHASE1 | HIV/AIDS | ACTIVE_NOT_RECRUITING | NCT04357821 |
| Protein Placebo | BIOLOGICAL | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |
| IHV01 Protein | BIOLOGICAL | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |
| B63521^11 gp120 | BIOLOGICAL | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |
| MVA/HIV62B Vaccine | BIOLOGICAL | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |
| GEO-D02 DNA | BIOLOGICAL | Phase PHASE1 | HIV Infections | WITHDRAWN | NCT04041674 |